A Multi-Site Tissue Repository Providing Annotated Biospecimens for Approved Investigator-Directed Biomedical Research Initiatives

Study Purpose:

At Sanguine, we consider ourselves the bridge between patients and researchers striving to find new treatments and diagnostics for numerous medical conditions. We collect biospecimens like blood for medical researchers. Donate from your home, track your sample, and help advance medical research.

Disease:

Amyotrophic Lateral Sclerosis (ALS),  Familial ALS,  Sporadic ALS, Primary Lateral Sclerosis (PLS), Hereditary Spastic Paraplegia (HSP), Healthy Volunteer, Healthy Volunteer with a Family History of ALS, Other

Study Type:

Observational Study

Study Category:

Other

Study Status:

Active, currently recruiting

Phase:

Not Applicable

Study Chair(s)/Principal Investigator(s):

Carlyn Crisostomo Sanguine Biosciences

Clinicaltrials.gov ID (11 digit #):

NCT01931644

Neals Affiliated?

No

Coordinating Center Contact Information

Sanguine Biosciences
Desiree Roman; Kristen Warren / .(JavaScript must be enabled to view this email address) / 877-864-3053; 877-864-3053
.(JavaScript must be enabled to view this email address) Los Angeles, California 91403 United States

Full Study Summary:

This study will collect blood and other optionally donated tissue samples from people with all different types of health conditions, as well as healthy control samples, in order to provide biomedical researchers with quality biospecimens that are necessary in translating basic science research into clinically relevant information and technology.

Study Sponsor:

Sanguine Biosciences

Participant Duration:

Estimated Enrollment:

2000

Estimated Study Start Date:

06/30/2013

Estimated Study Completion Date:

07/31/2020

Posting Last Modified Date:

02/29/2016

Date Study Added to alsconsortium.org:

08/19/2015
  • More Information

    Alternative Study Name: Be the Bridge Between Researchers and a Cure (GVHD, ALS, Hepatitis B, Alzheimer's Disease, Leukemia, and More)

    https://clinicalt...CT01931644&rank=1

  • Eligibility Criteria

    Gender:

    Female, Male

    Minimum Age:

    18

    Maximum Age:

    100

    Time since Symptom Onset:

    Time since Diagnosis:

    Can participants use Riluzole?


    Inclusion Criteria:
    All adults 18-100 years old
    Able to provide proof of diagnosis
    Live in USA

    Exclusion Criteria:
    Younger than 18 years old
    Receipt of blood products within 30 days of study blood collection
    Receipt of investigational drug within 30 days of study blood collection

  • Site Contact Information

    Sanguine Biosciences
    Pia Ahmed, Candace Shelton / .(JavaScript must be enabled to view this email address) / 818-804-2464; 480-768-7797
    Los Angeles, California 91403
    United States